man in red crew neck t-shirt and brown and white plaid button up shirt

4th COVID Vaccine Being Readied for Seniors

A new COVID vaccine is being readied for seniors, as the topological data analysis from the previous three vaccines shows that they are at a higher risk for contracting the disease. This new vaccine will be available in the coming weeks and will help protect seniors from the virus.

The vaccine is designed to protect against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. The vaccine is currently being trialed on seniors and those with weakened immune systems, as they are considered to be at highest risk for developing serious complications from the disease. The trial will assess the safety and efficacy of the vaccine in this population, and will help to determine whether it should be approved for general use. If the vaccine is found to be safe and effective, it could be a vital tool in protecting vulnerable populations from COVID-19.

All three other vaccines are available to people aged 18 years and above. However, the new vaccine is specifically designed for seniors, as they are at a higher risk for contracting the disease. This new vaccine will help protect seniors from the virus.

The other three vaccines available are:

  • The Pfizer-BioNTech COVID-19 Vaccine
  • The Moderna COVID-19 Vaccine
  • The Johnson & Johnson’s Janssen COVID-19 Vaccine

Benefits of Getting This Fourth Vaccine for Seniors Citizens 

Seniors are one of the most vulnerable groups when it comes to contracting COVID-19. According to the CDC, people aged 65 years and above are at a higher risk for severe illness from the virus. This is why it’s important for seniors to get the new vaccine, as it will help protect them from the virus.

Risks Associated With Getting Fourth Covid Vaccine Injection

There are always risks associated with getting any vaccine, including the new COVID vaccine. The most common side effects from the vaccine include pain and swelling at the injection site, fever, body aches, and fatigue. These side effects are usually mild and go away on their own within a few days.

Seniors should talk to their healthcare provider if they have any concerns about the vaccine. It’s always important to weigh the risks and benefits of any vaccine before getting it. Seniors should talk to their healthcare provider to learn more about the new COVID vaccine and whether or not it’s right for them.

How Seniors Citizens Can Get Access to New Vaccine 

The new vaccine will be available in the coming weeks. Seniors can talk to their healthcare provider to see if they are eligible for the vaccine. Eligibility criteria may vary depending on the country or state seniors live in.

Seniors should talk to their healthcare provider to learn more about the new COVID vaccine and how to get it. They can also visit their country or state’s website to learn more about the vaccine and how to get it. Seniors should get the new vaccine when it becomes available to help protect them from COVID-19.

The elderly are among the most vulnerable to the harmful effects of covid-19, and as such, it is vital that they receive the vaccine as soon as possible. The vaccine will help to protect them from becoming infected with the virus, and if they do contract it, the severity of their symptoms will be greatly reduced. In addition, getting vaccinated will help to reduce the spread of the virus among the elderly population. With so much at stake, it is essential that seniors get vaccinated as soon as possible. Senior citizens can receive the vaccine at their local doctor’s office, pharmacy, or hospital. They should also make sure to stay up-to-date on the latest information about the disease and how to protect themselves from it. By taking these simple steps, seniors can help to ensure their own health and safety and that of those around them.

6 Million Britons Eligible for COVID Vaccine Aren’t Getting Them

The number of people who have not been vaccinated is surprising. Recently, the authorities have confirmed quite a few cases of the Omicron Covid-19 variant in the UK. Approximately 80% of individuals aged 12 years or more had received 2 coronavirus vaccine doses across the UK as of December 4. This implies that approximately 6 million eligible individuals have not received vaccination yet in the country. Here, we will see who those people are.

Young people

It has been revealed by studies that it is mainly the young generation who have not been fully fascinated in England and Scotland. Approximately 33% of the English individuals aged between 18 years and 24 years have not received a double dose right now, which falls to 30% of individuals aged between 25 years and 29 years. As per Guardian analysis, Scotland has succeeded more in providing vaccines to young people. Approximately 67% of individuals aged 18 years or less have received the first dose in Scotland, unlike England where the number is just 53%.

Older individuals

There are nevertheless significant disparities in the uptake of vaccination at a local level amongst the older age groups. In Westminster, just 68% of the population more than 60 years of age have been fully vaccinated, which happens to be the lowest in the nation. As a matter of fact, London is lagging behind most of the other locations when it comes to vaccination coverage.

Asian and black people

There is a variation in vaccination rates by ethnicity as well and disparities are perceptible amongst the older age groups in particular. About 20% of black people whose age is more than 80 years remain unvaccinated. In contrast, almost all white individuals aged more than 80 years have received vaccination while approximately 10% of the South Asian individuals within the same age range haven’t received vaccination yet.

According to the most recent information, it has been shown that approximately 60% of the total population of the UK whose age is more than 40 years have received a 3rd vaccination right now.

In this era of increased concern about health, it is good to know that Mitocore by Ortho Molecular provides micronutrients, phytonutrients, and herbals for increased mitochondrial energy.

$29 Billion in Total Sales Expected for Pfizer Vaccine

Although COVID vaccinations have fallen short of goals, Pfizer announced in late 2021 that they expect COVID-19 vaccine sales to reach $65 billion or more through the end of the 2022 fiscal year. That figure represents an expected $29 billion in 2022, which is higher than what analysts expected from the efforts.

The American-based drugmaker created its COVID shot with the help of German partner BioNTech SE.

Pfizer says it’s looking to keep making deals for the vaccine with other countries, which could drive sales much higher than expected. The company announced that it expects to make up to four billion doses.

The sales figures are based on the revenues for 1.7 billion doses being sold. 

How Are the Other Vaccines Faring in Sales?

Moderna reached the market after Pfizer with its COVID vaccine. Although sales have been strong for it, the drugmaker struggled to ramp up production as much as its competitor. Sales in 2021 were revised to be as low as $15 billion, which is about half of what Pfizer was able to achieve.

During the first nine months of 2021, Johnson and Johnson earned just $766 million in revenues from its vaccine. The company announced that it expects several contracts to be fulfilled during the fiscal year’s fourth quarter, which should boost total sales to about $2.5 billion.

AstraZeneca is started to profit from its sales of the COVID vaccine they developed for distribution. The company earned about three times as much as J&J in 2021, with total sales expected to reach $9.74 billion across all its product lines. Vaccine sales reached nearly $2.2 billion. 

If you haven’t gotten your shot yet, experts recommend that you should as more variants emerge. You can also potentially boost immune system strength with Host Defense.

COVID Vaccination Rate Falls Short of July 4th Goal

In the opening days of President Joe Biden’s administration, he set a goal of having a 70% vaccination rate for eligible people before the Independence Day holiday in the United States. The country ended up falling just short of that goal, reaching 67% by July 4th.

Although the three percentage points aren’t that far off the desired number, they could have been reached or exceeded. The U.S. South has staggering low vaccination statistics, even with the Delta variant surge that happened during the summer.

Alabama had only 34% of its population fully vaccinated by the end of July. Arkansas wasn’t much better at 36%, while Louisiana had its figures at 37%.

The Delta Variant Caused a Surge of Vaccination Requests

When the Delta variant surges through the U.S. South, it became apparent that the most vulnerable people were those who hadn’t been vaccinated.

Over 90% of the registered infections came from those who hadn’t gotten a COVID shot or hadn’t completed their series. The percentage of hospitalizations was even higher.

Getting the word out about how transmissible the Delta variant is compared to the original coronavirus infections helped to push vaccination rates above 100% over the previous month. 

When all Americans are accounted for in every age group, about 50% were fully vaccinated by the end of July. 

Biden’s goal could have been reached if states like Wyoming, Idaho, Louisiana, Arkansas, Mississippi, and Alabama had hit 50% instead of being under 40%. For now, the best option we have is to wear a mask, stay socially distant, and stay healthy.

For some people, products like Neurobiologix and Quicksilver Scientific can work to potentially give their immune systems an extra boost to reach that goal. 

person holding white ballpoint pen

15 Million COVID-19 Vaccines Ruined After Ingredient Mix-up

Although the United States exceeded its vaccination goals since February 2021, the outcome hasn’t been flawless. A factory mix-up ruined up to 15 million doses of the single-shot Johnson & Johnson vaccine when a subcontractor mixed the ingredients from it with the AstraZeneca product.

Since the AstraZeneca vaccine is not available for distribution in the United States, the product was not usable.

The plant is run by Emergent BioSolutions, which partners with both single-shot producers. Regulators attributed the issue to human error, causing Johnson & Johnson to step up quality control procedures at the facility.

One Shot Speeds Up the Immunity Process in the United States

Although the two-shot vaccines for COVID-19 came out first, the Johnson & Johnson product receives a lot of credit for speeding along the immunity-building process in the United States. Once someone gets this shot, they’re considered immune after two weeks.

The setback was a major embarrassment for both companies involved in vaccine production. It would soon be followed by revelations that a rare side effect of the Johnson & Johnson vaccine involves blood clots that can appear three weeks after it gets administered.

To make up for the gap in vaccination opportunities, Pfizer started shipping its doses early. Moderna requested approval to send vials with 15 shots instead of ten to bolster the stock even further.

None of the tainted doses ever left the production facility. The mishap was reported to regulators immediately, and steps are in place to prevent future lapses.

The error has not affected any of the already delivered Johnson & Johnson doses. Additional deliveries from the Baltimore facility continue to remain in question.

$1.6 Billion Awarded to Novavax for a Coronavirus Vaccine

Novavax made headlines in 2020 because the company received $1.6 billion from the Trump Administration. The funds are the largest contract of its type for this struggling organization, one which has never brought a usable vaccine to the marketplace.

Why did Novavax get so much attention when other pharmaceutical companies with a better record of success were on the same path? In a rare move of bipartisanship in American politics, executives from the Bill and Melinda Gates Foundation promoted this small biotech company’s potential.

Republican officials in the White House agreed. The company uses moth cells to create crucial molecules faster than a typical vaccine, providing an advantage during the pandemic era that other companies couldn’t match.

The Company Was on the Verge of Collapse

Novavax made the push to the federal government for the $1.6 billion award after receiving almost $400 million from the Coalition for Epidemic Preparedness Innovations, headed by Dr. Richard Hatchett.

The funds are a dramatic turnaround for a company that was on the verge of collapse. After receiving the award, stock prices surged 30% almost overnight.

Novavax was on the verge of collapse. Their leading vaccine candidate was a product intended to prevent a deadly virus in newborns. It had failed for the second time in three years, causing the stock to trade so low that NASDAQ was threatening to delist it.

The company was raising cash by selling its manufacturing facilities.

How could the agency get so much money so quickly to produce a successful vaccine that it had never done before? The answer lies in a secretive mission called Operation Warp Speed.

What Is Operation Warp Speed?

Operation Warp Speed is a public-private partnership (PPP) initiated by the Trump Administration in April 2020. The goal of this effort was to accelerate the development, manufacturing, and distribution of vaccines to stop COVID-19. 

Congress allocated about $10 billion for this effort, including $3 billion for research through the National Institutes of Health.

Novavax received the $1.6 billion offer with one condition: it had to prove that its clinical trials were successful. If that happened, the money would help them to produce 100 million doses of the vaccine.

BioNTech and Pfizer received a $2 billion order with the same stipulation, getting 100 million doses of a safe and effective COVID-19 vaccine. In July 2020, GSK and Sanofi got funding of $2.1 billion.